REFERENCES
1. Zhu M, Li Y, Xu Q, Wang W, Liu Y, Liu Y. Acute myocardial infarction: molecular pathogenesis, diagnosis, and clinical management. MedComm. 2025;6:e70418.
2. Zhang T, Deng W, Deng Y, et al. Mechanisms of ferroptosis regulating oxidative stress and energy metabolism in myocardial ischemia-reperfusion injury and a novel perspective of natural plant active ingredients for its treatment. Biomed Pharmacother. 2023;165:114706.
3. Tsurusaki S, Kizana E. Mechanisms and therapeutic potential of multiple forms of cell death in myocardial ischemia-reperfusion injury. Int J Mol Sci. 2024;25:13492.
4. Xiang Q, Yi X, Zhu X, Wei X, Jiang D. Regulated cell death in myocardial ischemia-reperfusion injury. Trends Endocrinol Metab. 2024;35:219-34.
5. Liu Y, Li L, Wang Z, Zhang J, Zhou Z. Myocardial ischemia-reperfusion injury; molecular mechanisms and prevention. Microvasc Res. 2023;149:104565.
6. Qin Z, Kong B, Zheng J, Wang X, Li L. Alprostadil injection attenuates coronary microembolization-induced myocardial injury through GSK-3β/Nrf2/HO-1 signaling-mediated apoptosis inhibition. Drug Des Devel Ther. 2020;14:4407-22.
7. Yao M, Wang Z, Jiang L, et al. Oxytocin ameliorates high glucose- and ischemia/reperfusion-induced myocardial injury by suppressing pyroptosis via AMPK signaling pathway. Biomed Pharmacother. 2022;153:113498.
8. Timmermans AD, Balteau M, Gélinas R, et al. A-769662 potentiates the effect of other AMP-activated protein kinase activators on cardiac glucose uptake. Am J Physiol Heart Circ Physiol. 2014;306:H1619-30.
9. Zhang Q, Wang L, Wang S, et al. Signaling pathways and targeted therapy for myocardial infarction. Sig Transduct Target Ther. 2022;7:78.
10. Silverman N, Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev. 2001;15:2321-42.
11. Matter MA, Paneni F, Libby P, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J. 2024;45:89-103.
12. Han J, Lin L, Fang Z, et al. Cardiomyocyte-derived USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21. Theranostics. 2024;14:6236-48.
13. Ye B, Zhou H, Chen Y, et al. USP25 ameliorates pathological cardiac hypertrophy by stabilizing SERCA2a in cardiomyocytes. Circ Res. 2023;132:465-80.
14. Tong G, Chen Y, Chen X, et al. FGF18 alleviates hepatic ischemia-reperfusion injury via the USP16-mediated KEAP1/Nrf2 signaling pathway in male mice. Nat Commun. 2023;14:6107.
15. Zhong L, Dai S, Yu F, et al. Cardiomyocyte‐enriched USP20 ameliorates pathological cardiac hypertrophy by targeting STAT3 deubiquitination. Adv Sci. 2025;12:2416478.
16. Roberts MA, Deol KK, Mathiowetz AJ, et al. Parallel CRISPR-Cas9 screens identify mechanisms of PLIN2 and lipid droplet regulation. Dev Cell. 2023;58:1782-1800.e10.
17. Wang W, Zheng Y, Sun S, et al. A genome-wide CRISPR-based screen identifiesKAT7 as a driver of cellular senescence. Sci Transl Med. 2021;13:eabd2655.
18. Mircetic J, Camgöz A, Abohawya M, et al. CRISPR/Cas9 screen in gastric cancer patient‐derived organoids reveals KDM1A‐NDRG1 axis as a targetable vulnerability. Small Methods. 2023;7:2201605.
19. Tyagi A, Kaushal K, Chandrasekaran AP, et al. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells. Theranostics. 2022;12:5949-70.
20. Ma X, Jia S, Wang G, et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Sig Transduct Target Ther. 2023;8:246.
21. Arroyo JD, Jourdain AA, Calvo SE, et al. A genome-wide CRISPR death screen identifies genes essential for oxidative phosphorylation. Cell Metab. 2016;24:875-85.
22. Zhang Y, Qian H, Wu B, et al. E3 Ubiquitin ligase NEDD4 family-regulatory network in cardiovascular disease. Int. J. Biol. Sci. 2020;16:2727-40.
23. Bamborough P, Drewry D, Harper G, Smith GK, Schneider K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J Med Chem. 2008;51:7898-914.
25. Komander D, Clague MJ, Urbé S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009;10:550-63.
26. Wang ZV, Hill JA. Protein quality control and metabolism: bidirectional control in the heart. Cell Metab. 2015;21:215-26.
27. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction - alzheimer’s disease of the heart? N Engl J Med. 2013;368:455-64.
28. Seki T, Gong L, Williams AJ, Sakai N, Todi SV, Paulson HL. JosD1, a membrane-targeted deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility, and endocytosis. J Biol Chem. 2013;288:17145-55.
29. Xu J, Liang S, Wang Q, et al. JOSD2 mediates isoprenaline-induced heart failure by deubiquitinating CaMKIIδ in cardiomyocytes. Cell Mol Life Sci. 2024;81:18.
30. Yuan T, Zeng C, Liu J, et al. Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity. Sig Transduct Target Ther. 2024;9:11.
31. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251-62.
32. Dyck JRB, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol. 2006;574:95-112.
33. Potenza MA, Sgarra L, Nacci C, Leo V, De Salvia MA, Montagnani M. Activation of AMPK/SIRT1 axis is required for adiponectin-mediated preconditioning on myocardial ischemia-reperfusion (I/R) injury in rats. PLoS ONE. 2019;14:e0210654.
34. Ikeda Y, Sato K, Pimentel DR, et al. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J Biol Chem. 2009;284:35839-49.
35. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563-75.
36. Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2022;24:255-72.
37. Rossi FA, Rossi M. Emerging role of ubiquitin-specific protease 19 in oncogenesis and cancer development. Front. Cell Dev Biol. 2022;10:889166.
38. Li J, Johnson JA, Su H. Ubiquitin and ubiquitin-like proteins in cardiac disease and protection. Curr Drug Targets. 2018;19:989-1002.
39. Zhong H, Yao L, An H, et al. MrgD as a novel modeling and treatment target for pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2025;45:e164-83.
40. Li J, Minami I, Shiozaki M, et al. Human Pluripotent Stem Cell-Derived Cardiac Tissue-like Constructs for Repairing the Infarcted Myocardium. Stem Cell Rep. 2017;9:1546-59.
41. Gao L, Gregorich ZR, Zhu W, et al. Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac cells improve recovery from myocardial infarction in swine. Circulation. 2018;137:1712-30.
